TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00297479

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MBAT Group Therapy
Description: In-person group therapy/counseling (8 sessions over 8 weeks) using a Mindfulness-Based Addiction Treatment for nicotine dependence

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine
Description: 6 weeks of nicotine patch therapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nicotine
Description: 6 weeks of nicotine patch therapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nicotine
Description: 6 weeks of nicotine patch therapy

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Group Therapy
Description: In-person group therapy/counseling (8 sessions over 8 weeks) based upon Treating Tobacco Use and Dependence Clinical Practice Guideline
Study: NCT01517802

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abiraterone acetate
Description: Type=exact number, unit=mg, number=1000, form=tablet, route=oral, abiraterone acetate once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Type=exact number, unit=mg, number=5, form=tablet, route=oral, prednisone or prednisolone twice daily
Study: NCT04020770

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vibrating ball
Description: Parameters: 5 30-sec bouts of 68Hz vibration followed by a 1-minute rest.
Study: NCT00996996

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tositumomab and Iodine I 131 Tositumomab (Anti-B1 Antibody and Iodine-131 Anti-B1 Antibody)
Description: Dosimetric Dose: 450 mg of Anti-B1 Antibody infused over 70 minutes (inclusive of a 10-minute flush) immediately followed by 5 mCi (35 mg) of Iodine-131 Anti-B1 Antibody infused over 30 minutes (inclusive of a 10-minute flush).~Therapeutic Dose: Seven to 14 days after the dosimetric dose, 450 mg of Anti-B1 Antibody infused over 70 minutes (inclusive of a 10-minute flush), immediately followed by the patient-specific milliCurie activity (35 mg) of Iodine-131 Anti-B1 Antibody to deliver a total body dose (TBD) of 75 cGy infused over 30 minutes (inclusive of a 10-minute flush). Obese patients were dosed based upon 137% of their calculated lean body mass.
Study: NCT00534196

Intervention type: RADIATION
Intervention: Permanent iodine-125 (Brachytherapy)
Description: Observational research was conducted by grouping Brachytherapy with/without PI (permanent iodine) seed implantation.
Study: NCT01309620

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Zinc gluconate
Description: Zinc gluconate (GNC, USA), 100 mg twice daily

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo, Twice Daily
Study: NCT00297479

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Individual Therapy
Description: In-person individual counseling (4 sessions over 8 weeks) based upon Treating Tobacco Use and Dependence Clinical Practice Guideline
Study: NCT01878747

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Provider Tailored Intervention for Perioperative Stress
Description: Provider Tailored Intervention for Perioperative Stress (P-TIPS) is developed based on the proximal-distal theory that suggested that in acute procedural settings specific adult behaviors directly affect children's distress and coping behaviors. P-TIPS aims at reducing preoperative anxiety in children via modifying adults' behavior.
Study: NCT02884648

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: 15 mg/kg by vein on Day 1 of every 21-day study cycle.
Study: NCT02099838

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pioglitazone and Metformin
Description: taking 1 tablet twice a day (before breakfast and before dinner) orally for 12 weeks
Study: NCT00207714

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Golimumab
Description: Type=exact, unit=mg/ml, number= 50 to 100 , form=powder for solution for infusion, route=sub cutaneous.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MTX
Description: Type=exact, unit=mg/ml, number= 10, form=powder for solution for infusion, route=sub cutaneous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MTX
Description: Type=exact, unit=mg/ml, number= 10, form=powder for solution for infusion, route=sub cutaneous

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: MTX
Description: Type=exact, unit=mg/ml, number= 10, form=powder for solution for infusion, route=sub cutaneous

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Type=exact, unit=mg/ml, form=powder for solution for infusion, route=sub cutaneous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Infliximab
Description: Type=exact, unit=mg/ml number= 10, form=powder for solution for infusion, route=sub cutaneous
Study: NCT05450497

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Description: comparing sedative agents

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: comparing sedative agents

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine and propofol
Description: comparing sedative agents
Study: NCT02858856

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sipjeondaebo-tang
Description: Herbal medicine which is a compound of 10 herbs.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sipjeondaebo-tang
Description: Herbal medicine which is a compound of 10 herbs.
Study: NCT04953585

Intervention type: PROCEDURE
Intervention: radical gastrectomy
Description: According to the size and location of the tumor, the appropriate surgical method was selected for radical gastrectomy

Intervention type: PROCEDURE
Intervention: radical gastrectomy
Description: According to the size and location of the tumor, the appropriate surgical method was selected for radical gastrectomy
Study: NCT03764410

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Non-surgical periodontal treatment
Description: all the individuals included in the study received periodontal treatment with scaling and root planing with the use of local anesthesia and removal of factors that could cause biofilm retention such as fixed prosthesis, restorations, cervical abrasions. Four weekly sessions lasting 30 minutes each.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Non-surgical periodontal treatment
Description: all the individuals included in the study received periodontal treatment with scaling and root planing with the use of local anesthesia and removal of factors that could cause biofilm retention such as fixed prosthesis, restorations, cervical abrasions. Four weekly sessions lasting 30 minutes each.
Study: NCT04158479

Intervention type: DEVICE
Intervention: ECMO
Description: ECMO for circulatory and/or respiratory support

Intervention type: DEVICE
Intervention: ECMO
Description: ECMO for circulatory and/or respiratory support

Intervention type: DEVICE
Intervention: ECMO
Description: ECMO for circulatory and/or respiratory support
Study: NCT06545058

Intervention type: PROCEDURE
Intervention: Penile block
Description: Penile block with local anesthetics
Study: NCT01634022

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: 5 specific body acupoints (HT-7 and LI-4 on the hands bilaterally, and ST-36, SP-6, and LR-3 on the legs bilaterally) with gentle manual tonification every 10 min. Two acupoints along the midline of the head, GV-20 and GV-24.5 (Yintang), were also used with a 2 Hz current applied from GV-20 (-) to GV24.5 (+).
Study: NCT00624403

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Laryngeal mask insertion (LMA ProSeal)
Description: Laryngeal mask insertion

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Laryngeal mask insertion (I-Gel)
Description: Laryngeal mask insertion
Study: NCT00748813

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Influenza Vaccine, Formulation 2008-2009
Description: 1 dose of Surface Antigen, Inactivated, Influenza Vaccine, Formulation 2008-2009
Study: NCT02525328

Intervention type: OTHER
Intervention: blood or saliva specimen
Description: blood or saliva specimen is sampled for DNA extraction in CT family's members

Intervention type: OTHER
Intervention: blood or saliva specimen
Description: blood or saliva specimen is sampled for DNA extraction in CT family's members
Study: NCT02099838

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: taking 1 tablet twice a day (before breakfast and before dinner) orally for 12 weeks
Study: NCT01227889

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2118436
Description: 150 mg twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2118436
Description: 150 mg twice daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dacarbazine (DTIC)
Description: Intravenous (IV), 1000 mg/m2 every 3 weeks until initial progression
Study: NCT04256759

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dupilumab 300Mg Solution for Injection
Description: Subcutaneous (SC) dupilumab selected for this study is 300 mg every 2 weeks for 18 weeks.
Study: NCT01569516

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Octohydroaminoacridine Succinate Tablets
Description: 1mg, tid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Octohydroaminoacridine Succinate Tablets
Description: 1st-2nd week, 1mg, tid 3rd -16th week, 2mg, tid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Octohydroaminoacridine succinate Tablets
Description: 1st-2nd week, 1mg, tid, 3rd -4th week, 2mg, tid, 5th-16th week, 4mg, tid

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0mg, tid
Study: NCT03571061

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: whole colon water immersion and sigmoid water immersion
Description: we chose water immersion method instead of the triaditional method of carbon dioxide (CO2) insufflation.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: whole colon water immersion and sigmoid water immersion
Description: we chose water immersion method instead of the triaditional method of carbon dioxide (CO2) insufflation.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: whole colon water immersion and sigmoid water immersion
Description: we chose water immersion method instead of the triaditional method of carbon dioxide (CO2) insufflation.
Study: NCT01230697

Intervention type: DRUG
Intervention: Sorafenib
Description: Sorafenib 800mg/die oral
Study: NCT04480294

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HRS5091
Description: Single dose in group 1-5~Multiple doses in group 6-9

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HRS5091
Description: Single dose in group 1-5~Multiple doses in group 6-9

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HRS5091
Description: Single dose in group 1-5~Multiple doses in group 6-9

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HRS5091
Description: Single dose in group 1-5~Multiple doses in group 6-9

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HRS5091
Description: Single dose in group 1-5~Multiple doses in group 6-9
Study: NCT04603937

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KSI-301
Description: Intravitreal Injection
Study: NCT01308749

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxytocin
Description: Subjects will use the Syntocinon® Nasal Spray (oxytocin) twice daily for 8 weeks if they are randomized to that arm in the Randomized Phase. All subjects will use the Syntocinon® Nasal Spray twice daily for 8 weeks in the Open Label Phase.~Subjects ages 3-10 years old will be titrated up to a maximum dose of 24 International units (IU). Subjects ages 11-17 years old will be titrated up to a maximum dose of 32IU.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo Nasal Spray
Study: NCT04255160

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Estradiol (mylan or vivelle dot patch)
Description: Transdermal estradiol (0.1mg/day patch) will be used by women for 7 days. Administration of the patch will follow the package guidelines to change the patch after 3-4 days of use.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A placebo patch that is visually similar to the estradiol patch will be used for the group not receiving estradiol.
Study: NCT06349161

Intervention type: PROCEDURE
Intervention: One-trocar-assisted pyeloplasty
Description: Positioned in a full lateral decubitus posture. A 12mm incision was made below the 12th rib, followed by a muscle-sparing technique to access and open the Gerota's fascia. A 10mm balloon trocar was inserted, and CO2 was insufflated to a pressure of 12 mmHg at a flow rate of 3L. An operative scope with dual channels was introduced for retroperitoneal dissection, utilizing a peanut to expand the working space. The proximal ureter, UPJ, and renal pelvis were visualized, and the UPJ was mobilized and exteriorized under direct visualization to prevent torsion. Anderson-Hynes dismembered pyeloplasty was performed using a 6/0 PDS suture, with possible enlargement of the incision if necessary. A 4 French double J ureteral stent was inserted antegradely before completing the anastomosis, verified by methylene blue presence at the anastomotic site. A final retroperitoneoscopic assessment ensured proper alignment of the anastomosis, with closure of the incision site without drain placement.
Study: NCT04603937

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aflibercept
Description: Intravitreal Injection

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sham Procedure
Description: The sham is a procedure that mimics an intravitreal injection. It involves pressing the blunt end of an empty syringe (without a needle) against the anesthetized eye. It will be administered to participants in both treatments arms at applicable visits to maintain masking.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sham Procedure
Description: The sham is a procedure that mimics an intravitreal injection. It involves pressing the blunt end of an empty syringe (without a needle) against the anesthetized eye. It will be administered to participants in both treatments arms at applicable visits to maintain masking.
Study: NCT01454882

Intervention type: BEHAVIORAL
Intervention: Effects of Clothing
Description: There will be two temperature conditions; warm temperature \[WT, 75°F (24°C)\] and cool temperature \[CT, 60°F (16°C)\]. During each condition, subjects will vary the amount of clothing they are wearing at specified times

Intervention type: BEHAVIORAL
Intervention: Effects of Temperature
Description: There will be two temperature conditions; warm temperature \[WT, 75°F (24°C)\] and cool temperature \[CT, 60°F (16°C)\]. During each condition, subjects will vary the amount of clothing they are wearing at specified times

Intervention type: BEHAVIORAL
Intervention: Low Physical Activity
Description: This will be a randomized study with two within subject conditions (high and low physical activity levels)

Intervention type: BEHAVIORAL
Intervention: High Physical Activity
Description: This will be a randomized study with two within subject conditions (high and low physical activity levels)

Intervention type: BEHAVIORAL
Intervention: Direct calorimetry and doubly labeled water
Description: TDEE will be measured simultaneously for 14 days using direct calorimetry and doubly labeled water. A heterogeneous sample of adult men and women in stable health will be studied.
Study: NCT04181996

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Colchicine Oral Product
Description: Patients will be randomized to receive either placebo or colchicine

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: Patents will be randomized to receive either placebo or colchicine
Study: NCT03237611

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aprepitant 125 mg
Description: Patient scheduled for the first cycle of carboplatin-based chemotherapy will be offered to receive low doses of aprepitant (125mg of oral aprepitant) or 115mg of fosaprepitant intravenously for prevention of chemotherapy-induced nausea and vomiting

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fosaprepitant 115 MG
Description: Patient scheduled for the first cycle of carboplatin-based chemotherapy will be offered to receive low doses of aprepitant (125mg of oral aprepitant) or 115mg of fosaprepitant intravenously for prevention of chemotherapy-induced nausea and vomiting
Study: NCT03916237

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Referral to Medical Legal Partnership
Description: Medical Legal Partnership referral as described by the National Center for Medical Legal partnerships and others (Beck AF, Identifying and treating a substandard housing cluster using a medical-legal partnership. Pediatrics. 2012;130(5):831-838)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Referral to Medical Legal Partnership
Description: Medical Legal Partnership referral as described by the National Center for Medical Legal partnerships and others (Beck AF, Identifying and treating a substandard housing cluster using a medical-legal partnership. Pediatrics. 2012;130(5):831-838)
Study: NCT03237611

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone will be given as a part of standard CINV prophylaxis for patients receiving carboplatin-based chemotherapy, dosed at 20mg on day 1 of chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ondansetron 16 MG
Description: Ondansetron will be given as a part of standard CINV prophylaxis for patients receiving carboplatin-based chemotherapy, dosed at 16mg on day 1 of chemotherapy
Study: NCT01007591

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LEO 80190
Description: Applied once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydrocortisone
Description: Applied once daily
Study: NCT04440345

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IBI362
Description: Administered by subcutaneous injection
Study: NCT00448539

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rufinamide
Description: Dose will be maintained within the range of 2400 to 4800 mg/day (i.e., 1200 to 2400 mg twice daily).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rufinamide
Description: Dose will be maintained within the range of 2400 to 4800 mg/day (i.e., 1200 to 2400 mg twice daily).
Study: NCT04440345

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered by subcutaneous injection
Study: NCT03601832

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 4-D navigated stereotactic radiosurgical ablation
Description: 4-D Navigated Non-invasive radiosurgical ablation of ventricular tachycardia in patients with sustained monomorphic ventricular tachycardia/tachycardias after myocardial infarction.
Study: NCT04283383

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Primary Care Clinical Ultrasound Classroom (AECAP)
Description: A structured training process oriented to the clinical practice of the family physician, Primary Care Clinical Ultrasound Classroom (AECAP) will be carried out,
Study: NCT02370602

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-063
Description: TAK-063 tablets
Study: NCT05743790

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: RS2-control-RS4
Description: Group A: Treatment 1 = RS2 (Hi-Maize 260), Treatment 2 = Control (Amioca TF), Treatment 3 = RS4 (Versafibe 1490)

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: RS4-control-RS2
Description: Group B: Treatment 1 = RS4 (Versafibe 1490), Treatment 2 = Control (Amioca TF), Treatment 3 = RS2 (Hi-Maize 260)
Study: NCT03168685

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SureSource Engage application
Description: Eligible patients who choose to participate in the study will be asked to wear an actigraphy device \[ActiGraph GT9X Link Actigraph Link\] on their wrist continuously during both 4-week study phases.~The ActiGraph Link is a small (3.5 X 3.5 X 1 cm) wristwatch like device weighing approximately 14 grams that measures indicators of the wearer's activity and sleep patterns, including: acceleration, energy expenditure, steps, basal metabolic rate, activity intensity, sleep time, sleep efficiency, sleep latency, and body position.~The application being utilized is SureSource Engage application from Clinical Ink. The application is compatible to most Android and iOS devices.~Participants will also use a basic Bluetooth-enabled weight scale that syncs with the application.
Study: NCT02370602

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-063
Description: TAK-063 tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [^11C]T-773
Description: \[\^11C\]T-773 IV solution
Study: NCT05874869

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dihydroartemisinin-piperaquine
Description: The drug will be administered once a day for three consecutive days for three months (March, April, and May)
Study: NCT03210259

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Humira®
Description: Duration - 58 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 695501
Description: Duration - 58 weeks
Study: NCT03479385

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Integrative Medicine Intervention
Description: Study participants will attend 14 sessions with an Integrative Medicine clinician over the course of 6 months, potentially followed by a 6 month maintenance phase.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health Education Intervention
Description: Study participants will attend 14 sessions with a Health Educator over the course of 6 months.
Study: NCT03310203

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Iron
Description: Labelled iron

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Iron
Description: Labelled iron

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Iron
Description: Labelled iron
Study: NCT01871987

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FK949E
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FK949E
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FK949E
Description: oral
Study: NCT03016182

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Remote Ischemic Preconditioning
Description: RIPC will be induced during anesthesia by 3 cycles of 5-min upper limb ischemia and 5-min reperfusion using a blood-pressure cuff inflated to a pressure 200mmHg

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Control group witnout remote ischemic preconditioning